8-K
filed May 4, 2026, 7:59 PM ET
CIK 0001845459
debt
confidence high
sentiment neutral
materiality 0.65
NKGen Biotech, Inc.: debt financing — NKGen Biotech secures additional $607,200 convertible loan from AlpineBrook; consideration shares increased to 12.0M
NKGen Biotech, Inc.
- Additional loan of $607,200 (net $552,000 after $55,200 facilitation fee) from AlpineBrook Capital.
- New convertible note (Additional Note #1) bears interest at the Applicable Rate, converts at $0.08 per share.
- Consideration shares increased to 12,009,780, issuable in five installments over 25 months.
- Additional warrant issued to AlpineBrook for up to 3x principal/conversion price shares, exercise price $0.08, ten-year term.
- Voting agreement requires shareholders to authorize sufficient common stock for conversion and exercise of warrants.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
NKGen Biotech, Inc. incurred convertible notes of $607,200 with AlpineBrook Capital GP I Limited at Applicable Rate (as defined in the Loan Agreement) maturing Not explicitly stated beyond the ten-year warrant period.
- Instrument
- convertible notes
- Principal
- $607,200
- Counterparty
- AlpineBrook Capital GP I Limited
- Rate
- Applicable Rate (as defined in the Loan Agreement)
- Maturity
- Not explicitly stated beyond the ten-year warrant period
- Event
- incurrence
Exact text from the filing
and Exchange Commission (the “ SEC ”) on April 21, 2026). Pursuant to the Amendment, the Lender agreed to extend an additional loan to the Borrowers in the principal amount of $607,200 (the “ Additional Loan ”), which includes a facilitation fee of $55,200 that is fully earned by and owed to the Lender on the effective date and is included in the principal
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued common stock.
- Security
- common stock
Exact text from the filing
on April 28, 2026, the Company agreed to issue to the Lender the following securities
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued warrant for exercise price of $0.08 per share.
- Security
- warrant
- Consideration
- exercise price of $0.08 per share
Exact text from the filing
the Additional Warrant, which is exercisable for shares of Common Stock at an exercise price of $0.08 per share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued convertible note for conversion price of $0.08 per share.
- Security
- convertible note
- Consideration
- conversion price of $0.08 per share
Exact text from the filing
the Additional Note, which is convertible into shares of Common Stock at a conversion price of $0.08 per share
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NKGen Biotech, Inc. amended Omnibus Amendment to Secured Convertible Loan Agreement and Other Loan Documents with AlpineBrook Capital GP I Limited valued at principal amount of $607,200 (effective 2026-04-28).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- AlpineBrook Capital GP I Limited
- Value
- principal amount of $607,200
- Effective
- 2026-04-28
Exact text from the filing
On April 28, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ NKGen OpCo ,” and together with the Company, the “ Borrowers ”), entered into an Omnibus Amendment to Secured Convertible Loan Agreement and Other Loan Documents (the “ Amendment ”) with AlpineBrook Capital GP I Limited (the “ Lender ”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.